Login to Pancreatic Cancer UK

EUROPAC

A screening study to learn more about the genetic causes of pancreatic cancer in people with familial pancreatic cancer and hereditary pancreatitis (inflammation of the pancreas)

Why is this study being carried out?

Pancreatic cancer can sometimes run in families, where a small number of rare genetic conditions are linked to a higher risk of pancreatic cancer. The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) is an organisation involved in researching pancreatic cancer. There are two separate studies. One is looking at pancreatic cancer that runs in families (familial pancreatic cancer). The other is looking at hereditary pancreatitis.

Researchers hope to learn more about the genetic causes of pancreatic cancer. Being able to identify people at high risk of pancreatic cancer may also help researchers to develop new screening programmes to detect pancreatic cancer at an early stage.

Who is the study suitable for?

Familial pancreatic cancer registry

People from families with familial pancreatic cancer can join the study by:

  • completing questionnaires
  • giving a blood sample. The blood is tested by researchers to try to identify which genes may cause familial pancreatic cancer.

Hereditary pancreatitis registry

People with hereditary pancreatitis can join the study by:

  • completing questionnaires
  • giving a blood sample. The blood is taken after talking to an expert in pancreatic diseases and sometimes a geneticist (a specialist in genes) for genetic counselling. The blood may be tested for faults in genes known to cause pancreatic disease.

Read more about the EUROPAC studies here.

Recruitment start date: 30 October 2007

Recruitment end date: 30 September 2022

Information Standard

Published April 2016

Review date April 2018

  • Study centres

    The EUROPAC trial is being carried out at:

    • Royal Liverpool Hospital, Liverpool
    • Freeman Hospital in Newcastle
    • University College London Hospital, London
    • University Hospital Southampton, Southampton
    • Glasgow Royal Infirmary, Glasgow
    • Nottingham Queens Medical Centre, Nottingham
    • St James’s University Hospital, Leeds
    • North Bristol NHS Trust, Bristol

    Study lead

    Professor John Neoptolemos

    Contact information

    Anyone interested in taking part in the EUROPAC study can contact the team directly:

    Telephone: 0151 706 4168.

    Email: europac@liverpool.ac.uk 

    Division of Surgery and Oncology 
    University of Liverpool 
    5th Floor UCD Building, Royal Liverpool University Hospital 
    Daulby Street 
    Liverpool 
    L69 3GA

    You can also ask your GP or specialist to refer you. You have to be referred to take part in the secondary screening study.

  • How to join a study

    Please speak to your GP or consultant about whether this study is suitable for you.

    If you have any questions about pancreatic cancer you can speak to one of our specialist nurses on our Support Line.

    How to find out more

    For further information about this study please visit the EUROPAC website.                            

    You can also read about another trial called the EUROPAC-2 trial, which is for people with hereditary and long term (chronic) pancreatitis (inflammation of the pancreas). The trial wants to find out how effective tablets containing antioxidants or magnesium are in helping to reduce the symptoms of pain related to pancreatitis.

    For references used to develop this information please email us.